(Q33413210)

26 July 2017

title

Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (English)

1 reference

relapsed/refractory diffuse large B-cell lymphoma

26 July 2017

main subject

0 references

1 reference

10

Didier Blaise

1 reference

26 July 2017

Vadim Ivanov

1

1 reference

26 July 2017

Diane Coso

2

1 reference

26 July 2017

Bruno Chetaille

3

1 reference

26 July 2017

Benjamin Esterni

4

1 reference

26 July 2017

Daniel Olive

5

1 reference

26 July 2017

Therese Aurran-Schleinitz

6

1 reference

26 July 2017

Jean Marc Schiano

7

1 reference

26 July 2017

Anne-Marie Stoppa

8

1 reference

26 July 2017

Florence Broussais-Guillaumot

9

1 reference

26 July 2017

Reda Bouabdallah

11

1 reference

26 July 2017

publication date

17 March 2014

1 reference

26 July 2017

1 reference

26 July 2017

volume

55

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

2508-2513

1 reference

Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Immunomodulating drugs for chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.889822

10.3109/10428194.2014.889822

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference